Pharmaniaga

PHARMA

MYL7081OO002

Pharmaceuticals

End-of-day quote BURSA MALAYSIA Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
0.34 ^MYR	+1.49%		+1.49%	-11.69%

Apr. 19	China's drugmakers can't sell mRNA shots but haven't quit yet	RE
Mar. 27	Pharmaniaga Berhad Appoints Tuan Drs. Imam Fathorrahman as Independent and Non Executive Member of Audit Committee	CI

Pharmaniaga Berhad Announces First Interim Dividend for the Financial Year Ending December 31, 2021, Payable on July 6, 2021

May 21, 2021 at 08:39 am EDT

Pharmaniaga Berhad announced first interim dividend of 4.0 sen per share for the financial year ending December 31, 2021, payable on July 6, 2021. Ex-date is June 4, 2021. Entitlement date is June 8, 2021.

Latest news about Pharmaniaga

China's drugmakers can't sell mRNA shots but haven't quit yet	Apr. 19	RE
Pharmaniaga Berhad Appoints Tuan Drs. Imam Fathorrahman as Independent and Non Executive Member of Audit Committee	Mar. 27	CI
Pharmaniaga Berhad Appoints Tuan Drs. Imam Fathorrahman as Independent and Non Executive Member of Nomination and Remuneration Committee	Mar. 27	CI
Pharmaniaga Berhad Appoints Dato' Dr Faridah Aryani Binti Md Yusof as Independent and Non Executive Member of Risk Committee	Mar. 27	CI
Pharmaniaga Berhad Appoints Dato' Dr Faridah Aryani Binti Md Yusof as Independent and Non Executive Member of Nomination and Remuneration Committee	Mar. 27	CI
Pharmaniaga Berhad Appoints Dato' Mohd Zahir Bin Zahur Hussain as Independent and Non Executive Chairman of Risk Committee	Mar. 27	CI
Pharmaniaga Berhad Announces Redesignation of Puan Sarah Azreen Binti Abdul Samat from Chairman of Risk Committee to Member of Risk Committee	Mar. 27	CI
Pharmaniaga Berhad Appoints Dato' Mohd Zahir Bin Zahur Hussain as Independent and Non Executive Member of Audit Committee	Mar. 27	CI
Pharmaniaga Berhad Announces the Retirement of Encik Mohamed Iqbal Abdul Rahman as Chief Operating Officer	Mar. 08	CI
Pharmaniaga Trims Loss in Q4 2024	Mar. 03	MT
Pharmaniaga Berhad Appoints Tuan Drs. Imam Fathorrahman as Independent and Non Executive Director, Effective March 1, 2024	Feb. 29	CI
Pharmaniaga Berhad Appoints Encik Zulkifli Bin Jafar as Executive Director, Effective March 1, 2024	Feb. 29	CI
Pharmaniaga Berhad Appoints Dato Mohd Zahir Bin Zahur Hussain as Independent and Non Executive Director, Effective from March 1, 2024	Feb. 29	CI
Pharmaniaga Berhad Appoints Dato' Dr Faridah Aryani Binti Md Yusof, as Independent and Non Executive Director Effective March 1, 2024	Feb. 29	CI
Pharmaniaga Berhad Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 29	CI
Pharmaniaga Berhad Announces Resignation of Puan Dayana Rogayah Binti Omar as Non Independent and Non Executive Alternate Director	Feb. 19	CI
Pharmaniaga, Malaysia's Health Ministry Sign Seven-Year Consession Deal	Jan. 04	MT
Pharmaniaga Berhad Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 29	CI
Bourse Denies Pharmaniaga's Private Placement Appeal	23-09-18	MT
Pharmaniaga Logs Higher Profit, Revenue in Q2	23-08-14	MT
Pharmaniaga Berhad Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Pharmaniaga Berhad Announces Re-Designation of Puan Sarah Azreen Abdul Samat from Member of Risk Committee to Chairman of Risk Committee	23-08-10	CI
Pharmaniaga Berhad Announces Appointment of Encik Ahmad Shahredzuan Mohd Shariff as Non Independent and Non Executive Member of Risk Committee	23-08-10	CI
Pharmaniaga Berhad Appoints Puan Dayana Rogayah Binti Omar as Non Independent and Non Executive Alternate Director	23-08-10	CI
Pharmaniaga Berhad Appoints Encik Mohammad Ashraf Bin Md. Radzi as Non Independent and Non Executive Director	23-08-10	CI

Chart Pharmaniaga

Duration

Period

More charts

Company Profile

Pharmaniaga Berhad is an investment holding company. The Company is principally engaged in the research and development, manufacturing of generic drugs and medical devices, logistics and distribution, sales, and marketing, as well as community pharmacy. The Company operates through three segments: Logistics and distribution, Manufacturing, and Indonesia. The Logistics and distribution is engaged in the distribution, trading and wholesaling of pharmaceutical and medical products as well as supply and installation of medical and hospital equipment in Malaysia. The Manufacturing segment is engaged in the manufacturing of pharmaceutical products in Malaysia. Indonesia segment is engaged in the manufacturing and distribution of pharmaceutical and medical products in Indonesia. The Companyâs subsidiaries include Idaman Pharma Manufacturing Sdn. Bhd., Pharmaniaga Manufacturing Berhad, Pharmaniaga LifeScience Sdn. Bhd., Pharmaniaga Logistics Sdn. Bhd., and Pharmaniaga Marketing Sdn. Bhd.

Sector

Pharmaceuticals

Calendar

2024-05-14 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Pharmaniaga

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

SELL

Number of Analysts

Last Close Price

0.34 MYR

Average target price

0.31 MYR

Spread / Average Target

-8.82%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Pharmaceuticals Wholesale

	1st Jan change	Capi.
PHARMANIAGA	-11.69%	101M
MCKESSON CORPORATION	+17.35%	70.95B
SINOPHARM GROUP CO. LTD.	+5.38%	8.67B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+6.69%	8.16B
HUADONG MEDICINE CO., LTD	-20.96%	7.91B
H. LUNDBECK A/S	+0.49%	4.51B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	+17.12%	4.31B
EBOS GROUP LIMITED	-3.38%	4.07B
GALENICA AG	-2.61%	3.84B
CHINA NATIONAL MEDICINES CORPORATION LTD.	+22.08%	3.63B

Pharmaceuticals Wholesale

Pharmaniaga

Equities

PHARMA

MYL7081OO002

Pharmaceuticals

Pharmaniaga Berhad Announces First Interim Dividend for the Financial Year Ending December 31, 2021, Payable on July 6, 2021

Latest news about Pharmaniaga

Chart Pharmaniaga

Company Profile

Income Statement Evolution

Ratings for Pharmaniaga

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Pharmaceuticals Wholesale